Multikinase Inhibitor - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510243250

Publication Date:

October 2, 2024

Pages:

134

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Multikinase inhibitors (MKIs) are small molecule inhibitors of multiple, membrane-bound and intracellular kinases involved in various normal cellular functions and pathologic processes including, oncogenesis, tumour angiogenesis, metastasis, tumour immunity, maintenance of the tumour microenvironment and apoptosis.
The global market for Multikinase Inhibitor was estimated to be worth US$ 57610 million in 2023 and is forecast to a readjusted size of US$ 94210 million by 2030 with a CAGR of 7.3% during the forecast period 2024-2030
麻豆原创 Drivers:
Rising cancer burden: The increasing prevalence of various cancers, particularly solid tumors, fuels the demand for targeted therapies like multikinase inhibitors.
Targeted efficacy: Unlike traditional chemotherapy, multikinase inhibitors target specific protein kinases involved in cancer cell growth and survival, leading to more precise and potentially less toxic treatment.
Expanding pipeline and approvals: Continuous research and development efforts are yielding promising new multikinase inhibitors, with several gaining regulatory approval for different cancer types.
Combination therapy potential: Multikinase inhibitors often synergize well with other treatment modalities, offering potential for improved treatment outcomes.
Challenges and Opportunities:
High cost of treatment: Multikinase inhibitors can be expensive, posing a challenge for access and affordability in some healthcare systems.
Off-target effects and resistance: Managing potential side effects and developing strategies to overcome drug resistance remain areas of active research.
Complex regulatory landscape: Navigating diverse regulatory requirements across different countries can hinder market access for new drugs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Multikinase Inhibitor, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Multikinase Inhibitor by region & country, by Type, and by Application.
The Multikinase Inhibitor market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multikinase Inhibitor.
麻豆原创 Segmentation
By Company
Novartis
Bayer
Mylan
Pfizer
Sanofi
Dr. Reddy's Laboratories
Teva Pharmaceutical
Eisai
Everest Pharmaceuticals
Shilpa Medicare
Exelixis
MSN Laboratories
Natco Pharma
Cipla
Glenmark Pharmaceuticals Ltd.
Hetero Drugs Limited
Huateng Pharmaceutical
Bio Nova Pharmaceuticals Private Limited
Segment by Type:
Capsule
Tablet
Others
Segment by Application
Kidney Cancer
Liver Cancer
Thyroid Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Multikinase Inhibitor manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Multikinase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Multikinase Inhibitor in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Multikinase Inhibitor Product Introduction
1.2 Global Multikinase Inhibitor 麻豆原创 Size Forecast
1.3 Multikinase Inhibitor 麻豆原创 Trends & Drivers
1.3.1 Multikinase Inhibitor Industry Trends
1.3.2 Multikinase Inhibitor 麻豆原创 Drivers & Opportunity
1.3.3 Multikinase Inhibitor 麻豆原创 Challenges
1.3.4 Multikinase Inhibitor 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Multikinase Inhibitor Players Revenue Ranking (2023)
2.2 Global Multikinase Inhibitor Revenue by Company (2019-2024)
2.3 Key Companies Multikinase Inhibitor Manufacturing Base Distribution and Headquarters
2.4 Key Companies Multikinase Inhibitor Product Offered
2.5 Key Companies Time to Begin Mass Production of Multikinase Inhibitor
2.6 Multikinase Inhibitor 麻豆原创 Competitive Analysis
2.6.1 Multikinase Inhibitor 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Multikinase Inhibitor Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multikinase Inhibitor as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Capsule
3.1.2 Tablet
3.1.3 Others
3.2 Global Multikinase Inhibitor Sales Value by Type
3.2.1 Global Multikinase Inhibitor Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Multikinase Inhibitor Sales Value, by Type (2019-2030)
3.2.3 Global Multikinase Inhibitor Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Kidney Cancer
4.1.2 Liver Cancer
4.1.3 Thyroid Cancer
4.1.4 Others
4.2 Global Multikinase Inhibitor Sales Value by Application
4.2.1 Global Multikinase Inhibitor Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Multikinase Inhibitor Sales Value, by Application (2019-2030)
4.2.3 Global Multikinase Inhibitor Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Multikinase Inhibitor Sales Value by Region
5.1.1 Global Multikinase Inhibitor Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Multikinase Inhibitor Sales Value by Region (2019-2024)
5.1.3 Global Multikinase Inhibitor Sales Value by Region (2025-2030)
5.1.4 Global Multikinase Inhibitor Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Multikinase Inhibitor Sales Value, 2019-2030
5.2.2 North America Multikinase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Multikinase Inhibitor Sales Value, 2019-2030
5.3.2 Europe Multikinase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Multikinase Inhibitor Sales Value, 2019-2030
5.4.2 Asia Pacific Multikinase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Multikinase Inhibitor Sales Value, 2019-2030
5.5.2 South America Multikinase Inhibitor Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Multikinase Inhibitor Sales Value, 2019-2030
5.6.2 Middle East & Africa Multikinase Inhibitor Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Multikinase Inhibitor Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Multikinase Inhibitor Sales Value
6.3 United States
6.3.1 United States Multikinase Inhibitor Sales Value, 2019-2030
6.3.2 United States Multikinase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Multikinase Inhibitor Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Multikinase Inhibitor Sales Value, 2019-2030
6.4.2 Europe Multikinase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Multikinase Inhibitor Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Multikinase Inhibitor Sales Value, 2019-2030
6.5.2 China Multikinase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.5.3 China Multikinase Inhibitor Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Multikinase Inhibitor Sales Value, 2019-2030
6.6.2 Japan Multikinase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Multikinase Inhibitor Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Multikinase Inhibitor Sales Value, 2019-2030
6.7.2 South Korea Multikinase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Multikinase Inhibitor Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Multikinase Inhibitor Sales Value, 2019-2030
6.8.2 Southeast Asia Multikinase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Multikinase Inhibitor Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Multikinase Inhibitor Sales Value, 2019-2030
6.9.2 India Multikinase Inhibitor Sales Value by Type (%), 2023 VS 2030
6.9.3 India Multikinase Inhibitor Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis
7.1.1 Novartis Profile
7.1.2 Novartis Main Business
7.1.3 Novartis Multikinase Inhibitor Products, Services and Solutions
7.1.4 Novartis Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.1.5 Novartis Recent Developments
7.2 Bayer
7.2.1 Bayer Profile
7.2.2 Bayer Main Business
7.2.3 Bayer Multikinase Inhibitor Products, Services and Solutions
7.2.4 Bayer Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.2.5 Bayer Recent Developments
7.3 Mylan
7.3.1 Mylan Profile
7.3.2 Mylan Main Business
7.3.3 Mylan Multikinase Inhibitor Products, Services and Solutions
7.3.4 Mylan Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.3.5 Pfizer Recent Developments
7.4 Pfizer
7.4.1 Pfizer Profile
7.4.2 Pfizer Main Business
7.4.3 Pfizer Multikinase Inhibitor Products, Services and Solutions
7.4.4 Pfizer Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.4.5 Pfizer Recent Developments
7.5 Sanofi
7.5.1 Sanofi Profile
7.5.2 Sanofi Main Business
7.5.3 Sanofi Multikinase Inhibitor Products, Services and Solutions
7.5.4 Sanofi Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi Recent Developments
7.6 Dr. Reddy's Laboratories
7.6.1 Dr. Reddy's Laboratories Profile
7.6.2 Dr. Reddy's Laboratories Main Business
7.6.3 Dr. Reddy's Laboratories Multikinase Inhibitor Products, Services and Solutions
7.6.4 Dr. Reddy's Laboratories Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.6.5 Dr. Reddy's Laboratories Recent Developments
7.7 Teva Pharmaceutical
7.7.1 Teva Pharmaceutical Profile
7.7.2 Teva Pharmaceutical Main Business
7.7.3 Teva Pharmaceutical Multikinase Inhibitor Products, Services and Solutions
7.7.4 Teva Pharmaceutical Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.7.5 Teva Pharmaceutical Recent Developments
7.8 Eisai
7.8.1 Eisai Profile
7.8.2 Eisai Main Business
7.8.3 Eisai Multikinase Inhibitor Products, Services and Solutions
7.8.4 Eisai Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.8.5 Eisai Recent Developments
7.9 Everest Pharmaceuticals
7.9.1 Everest Pharmaceuticals Profile
7.9.2 Everest Pharmaceuticals Main Business
7.9.3 Everest Pharmaceuticals Multikinase Inhibitor Products, Services and Solutions
7.9.4 Everest Pharmaceuticals Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.9.5 Everest Pharmaceuticals Recent Developments
7.10 Shilpa Medicare
7.10.1 Shilpa Medicare Profile
7.10.2 Shilpa Medicare Main Business
7.10.3 Shilpa Medicare Multikinase Inhibitor Products, Services and Solutions
7.10.4 Shilpa Medicare Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.10.5 Shilpa Medicare Recent Developments
7.11 Exelixis
7.11.1 Exelixis Profile
7.11.2 Exelixis Main Business
7.11.3 Exelixis Multikinase Inhibitor Products, Services and Solutions
7.11.4 Exelixis Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.11.5 Exelixis Recent Developments
7.12 MSN Laboratories
7.12.1 MSN Laboratories Profile
7.12.2 MSN Laboratories Main Business
7.12.3 MSN Laboratories Multikinase Inhibitor Products, Services and Solutions
7.12.4 MSN Laboratories Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.12.5 MSN Laboratories Recent Developments
7.13 Natco Pharma
7.13.1 Natco Pharma Profile
7.13.2 Natco Pharma Main Business
7.13.3 Natco Pharma Multikinase Inhibitor Products, Services and Solutions
7.13.4 Natco Pharma Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.13.5 Natco Pharma Recent Developments
7.14 Cipla
7.14.1 Cipla Profile
7.14.2 Cipla Main Business
7.14.3 Cipla Multikinase Inhibitor Products, Services and Solutions
7.14.4 Cipla Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.14.5 Cipla Recent Developments
7.15 Glenmark Pharmaceuticals Ltd.
7.15.1 Glenmark Pharmaceuticals Ltd. Profile
7.15.2 Glenmark Pharmaceuticals Ltd. Main Business
7.15.3 Glenmark Pharmaceuticals Ltd. Multikinase Inhibitor Products, Services and Solutions
7.15.4 Glenmark Pharmaceuticals Ltd. Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.15.5 Glenmark Pharmaceuticals Ltd. Recent Developments
7.16 Hetero Drugs Limited
7.16.1 Hetero Drugs Limited Profile
7.16.2 Hetero Drugs Limited Main Business
7.16.3 Hetero Drugs Limited Multikinase Inhibitor Products, Services and Solutions
7.16.4 Hetero Drugs Limited Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.16.5 Hetero Drugs Limited Recent Developments
7.17 Huateng Pharmaceutical
7.17.1 Huateng Pharmaceutical Profile
7.17.2 Huateng Pharmaceutical Main Business
7.17.3 Huateng Pharmaceutical Multikinase Inhibitor Products, Services and Solutions
7.17.4 Huateng Pharmaceutical Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.17.5 Huateng Pharmaceutical Recent Developments
7.18 Bio Nova Pharmaceuticals Private Limited
7.18.1 Bio Nova Pharmaceuticals Private Limited Profile
7.18.2 Bio Nova Pharmaceuticals Private Limited Main Business
7.18.3 Bio Nova Pharmaceuticals Private Limited Multikinase Inhibitor Products, Services and Solutions
7.18.4 Bio Nova Pharmaceuticals Private Limited Multikinase Inhibitor Revenue (US$ Million) & (2019-2024)
7.18.5 Bio Nova Pharmaceuticals Private Limited Recent Developments
8 Industry Chain Analysis
8.1 Multikinase Inhibitor Industrial Chain
8.2 Multikinase Inhibitor Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Multikinase Inhibitor Sales Model
8.5.2 Sales Channel
8.5.3 Multikinase Inhibitor Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Novartis
Bayer
Mylan
Pfizer
Sanofi
Dr. Reddy's Laboratories
Teva Pharmaceutical
Eisai
Everest Pharmaceuticals
Shilpa Medicare
Exelixis
MSN Laboratories
Natco Pharma
Cipla
Glenmark Pharmaceuticals Ltd.
Hetero Drugs Limited
Huateng Pharmaceutical
Bio Nova Pharmaceuticals Private Limited

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.